Replies to post #2551 on BrainStorm Cell Therapeutics Inc (BCLI)

[Chief-money]

5,000 new cases ALS in US each year. Assuming a portion get NurOwn (hard to imagine not all demanding to get it which they are now) 3,000 x 100K cost annually treatment = 300M revenues. And that’s only in US and not even considering existing ALS patients. Now consider the #’s for MS which are considerably higher. I’m thinking buyout now for company based on results we saw in phase 2 and the few patients showing reversal of symptoms in phase 3 a reasonable buyout is $800M-$1.2B. Buyout price will jump to $1.5-3B when we get FDA approval for ALS. Look at DYAX buyout when they were in phase 3 waiting on FDA approval. $BCLI